MX2023000658A - Composiciones utiles para el tratamiento de la enfermedad de charcot-marie-tooth. - Google Patents

Composiciones utiles para el tratamiento de la enfermedad de charcot-marie-tooth.

Info

Publication number
MX2023000658A
MX2023000658A MX2023000658A MX2023000658A MX2023000658A MX 2023000658 A MX2023000658 A MX 2023000658A MX 2023000658 A MX2023000658 A MX 2023000658A MX 2023000658 A MX2023000658 A MX 2023000658A MX 2023000658 A MX2023000658 A MX 2023000658A
Authority
MX
Mexico
Prior art keywords
coding sequence
human
mirna
compositions useful
mitofusin
Prior art date
Application number
MX2023000658A
Other languages
English (en)
Spanish (es)
Inventor
Christian Hinderer
James M Wilson
Eileen Workman
Original Assignee
Univ Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pennsylvania filed Critical Univ Pennsylvania
Publication of MX2023000658A publication Critical patent/MX2023000658A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y306/00—Hydrolases acting on acid anhydrides (3.6)
    • C12Y306/05—Hydrolases acting on acid anhydrides (3.6) acting on GTP; involved in cellular and subcellular movement (3.6.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
MX2023000658A 2020-07-13 2021-07-13 Composiciones utiles para el tratamiento de la enfermedad de charcot-marie-tooth. MX2023000658A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063051336P 2020-07-13 2020-07-13
US202163173045P 2021-04-09 2021-04-09
PCT/US2021/041406 WO2022015715A1 (en) 2020-07-13 2021-07-13 Compositions useful for treatment of charcot-marie-tooth disease

Publications (1)

Publication Number Publication Date
MX2023000658A true MX2023000658A (es) 2023-02-23

Family

ID=77317406

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023000658A MX2023000658A (es) 2020-07-13 2021-07-13 Composiciones utiles para el tratamiento de la enfermedad de charcot-marie-tooth.

Country Status (14)

Country Link
US (1) US20230270884A1 (cg-RX-API-DMAC7.html)
EP (1) EP4179097A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023534037A (cg-RX-API-DMAC7.html)
KR (1) KR20230038503A (cg-RX-API-DMAC7.html)
CN (1) CN116438311A (cg-RX-API-DMAC7.html)
AU (1) AU2021309645A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023000578A2 (cg-RX-API-DMAC7.html)
CA (1) CA3185281A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023001500A2 (cg-RX-API-DMAC7.html)
IL (1) IL299762A (cg-RX-API-DMAC7.html)
MX (1) MX2023000658A (cg-RX-API-DMAC7.html)
TW (1) TW202216244A (cg-RX-API-DMAC7.html)
WO (1) WO2022015715A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202300505B (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201907882D0 (en) 2019-06-03 2019-07-17 Cyprus Foundation For Muscular Dystrophy Res Methods
PE20241891A1 (es) * 2021-09-01 2024-09-19 Jaguar Gene Therapy Llc Vectores y viriones adenoasociados para tratar la galactosemia y metodos de uso y fabricacion
WO2023049846A1 (en) * 2021-09-24 2023-03-30 The Trustees Of The University Of Pennsylvania Compositions useful for treatment of charcot-marie-tooth disease
EP4634394A2 (en) 2022-12-17 2025-10-22 The Trustees of The University of Pennsylvania Recombinant aav mutant vectors with cardiac and skeletal muscle-specific targeting motifs and compositions containing same
WO2024130070A2 (en) 2022-12-17 2024-06-20 The Trustees Of The University Of Pennsylvania Recombinant aav capsids with cardiac- and skeletal muscle- specific targeting motifs and uses thereof
WO2024155966A1 (en) * 2023-01-20 2024-07-25 Loma Linda University Health Methods and compositions for treatment of niemann-pick disease type c and charcot-marie-tooth disease
WO2024261139A1 (en) 2023-06-21 2024-12-26 Fundació Institut De Recerca Biomèdica (Irb Barcelona) Variants of mfn2 and their use in the treatment/prevention of diseases associated with alterations in endoplasmatic reticulum function
WO2025007046A1 (en) 2023-06-29 2025-01-02 The Trustees Of The University Of Pennsylvania Mutant aav with central nervous system targeting motifs and compositions containing same
KR20260114566A (ko) 2023-11-14 2026-07-22 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 심근 및 골격근-특이적 표적화 모티프를 갖는 조성물 및 이의 용도

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6759237B1 (en) 1998-11-05 2004-07-06 The Trustees Of The University Of Pennsylvania Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same
CN103589692B (zh) 2001-11-13 2018-07-24 宾夕法尼亚大学托管会 检测和/或鉴定腺伴随病毒(aav)序列以及分离所鉴定的新型序列的方法
DK2359869T3 (en) 2001-12-17 2019-04-15 Univ Pennsylvania Sequences of adeno-associated virus (AAV) serotype 8, vectors containing these, and uses thereof
EP1668143B1 (en) 2003-09-30 2013-03-20 The Trustees of The University of Pennsylvania Adeno-associated virus (aav) clades, sequences, vectors containing same, and uses therefor
DE23193606T1 (de) 2005-04-07 2024-02-15 The Trustees Of The University Of Pennsylvania Verfahren zur erhöhung der funktion eines aav-vektors
US7588772B2 (en) 2006-03-30 2009-09-15 Board Of Trustees Of The Leland Stamford Junior University AAV capsid library and AAV capsid proteins
WO2010053572A2 (en) 2008-11-07 2010-05-14 Massachusetts Institute Of Technology Aminoalcohol lipidoids and uses thereof
WO2011126808A2 (en) 2010-03-29 2011-10-13 The Trustees Of The University Of Pennsylvania Pharmacologically induced transgene ablation system
EP3391877A1 (en) 2010-04-08 2018-10-24 The Trustees of Princeton University Preparation of lipid nanoparticles
US8853377B2 (en) 2010-11-30 2014-10-07 Shire Human Genetic Therapies, Inc. mRNA for use in treatment of human genetic diseases
KR20220025112A (ko) 2011-06-08 2022-03-03 샤이어 휴먼 지네틱 테라피즈 인크. Mrna 전달을 위한 지질 나노입자 조성물 및 방법
FR2977562B1 (fr) 2011-07-06 2016-12-23 Gaztransport Et Technigaz Cuve etanche et thermiquement isolante integree dans une structure porteuse
EA037448B1 (ru) 2012-06-08 2021-03-30 Этрис Гмбх Способ доставки в легкие терапевтической мрнк с pei и фармацевтическая композиция
US20150366997A1 (en) 2012-12-07 2015-12-24 Shire Human Genetics Therapies, Inc. COMPOSITIONS AND METHODS FOR mRNA DELIVERY
CN110003066B (zh) 2013-11-18 2021-09-03 阿克丘勒斯治疗公司 用于rna递送的可电离的阳离子脂质
US11015174B2 (en) 2015-12-11 2021-05-25 The Trustees Of The University Of Pennsylvania Scalable purification method for AAV8
WO2017100674A1 (en) 2015-12-11 2017-06-15 The Trustees Of The University Of Pennsylvania Scalable purification method for aav1
EP3992283A1 (en) 2015-12-11 2022-05-04 The Trustees Of The University Of Pennsylvania Scalable purification method for aavrh10
EP3387138B2 (en) 2015-12-11 2026-05-27 The Trustees Of The University Of Pennsylvania Scalable purification method for aav9
RS65241B1 (sr) 2017-02-28 2024-03-29 Univ Pennsylvania Vektor adeno-asociranih virusa (aav) iz podgrupe f i njegove upotrebe
WO2018168956A1 (ja) 2017-03-16 2018-09-20 株式会社デンソー 自己位置推定装置
IL276859B2 (en) 2018-02-27 2025-12-01 Univ Pennsylvania Novel adeno-associated virus (aav) vectors, aav vectors having reduced capsid deamidation and uses therefor
EP3768695A4 (en) 2018-02-27 2022-04-06 The Trustees of the University of Pennsylvania NOVEL ADENO-ASSOCIATED VIRUS (AAV) VECTORS, AAV VECTORS WITH REDUCED CAPSIID DEAMIDATION AND USES THEREOF
AU2019328270B2 (en) * 2018-08-29 2026-02-26 Research Institute At Nationwide Children's Hospital Products and methods for inhibition of expression of mutant GARS protein
MX2021007600A (es) 2018-12-21 2021-08-11 Univ Pennsylvania Composiciones para la reduccion de la expresion transgenica especifica de drg.

Also Published As

Publication number Publication date
IL299762A (en) 2023-03-01
EP4179097A1 (en) 2023-05-17
WO2022015715A1 (en) 2022-01-20
US20230270884A1 (en) 2023-08-31
CO2023001500A2 (es) 2023-05-19
JP2023534037A (ja) 2023-08-07
AU2021309645A1 (en) 2023-02-09
BR112023000578A2 (pt) 2023-05-09
CN116438311A (zh) 2023-07-14
ZA202300505B (en) 2023-09-27
CA3185281A1 (en) 2022-01-20
KR20230038503A (ko) 2023-03-20
TW202216244A (zh) 2022-05-01

Similar Documents

Publication Publication Date Title
ZA202300505B (en) Compositions useful for treatment of charcot-marie-tooth disease
PH12021551341A1 (en) Compositions for drg-specific reduction of transgene expression
MY209860A (en) Gene therapy vectors for treating heart disease
WO2022076803A8 (en) Compositions and methods for treatment of fabry disease
MX2023007574A (es) "vacuna de arn contra variantes de sars-cov-2.
MX2023011035A (es) Composición de terapia génica y tratamiento de la miocardiopatía arritmogénica del ventriculo derecho.
MX2021013420A (es) Composiciones utiles en el tratamiento de leucodistrofia metacromatica.
JOP20190200A1 (ar) تركيبات نافعة في معالجة ضمور العضل النخاعي
PH12021552638A1 (en) Compositions useful for treatment of pompe disease
CL2020000295A1 (es) Métodos de terapia génica del factor viii (fviii)
MX2022014258A (es) Composiciones para la reducción específica de un fármaco de la expresión de transgén.
JPWO2019156137A5 (cg-RX-API-DMAC7.html)
JP2014506787A5 (cg-RX-API-DMAC7.html)
MX2022013411A (es) Genes gla con codones optimizados y usos de los mismos.
MX2023013394A (es) Composiciones de suministro de terapia genica y metodos para tratar perdida auditiva.
WO2021226485A3 (en) Antisense therapeutics for betacoronavirus treatment
AR037038A1 (es) Una composicion y metodo para alterar la masa corporal magra y las propiedades oseas en un sujeto
BR112022001025A2 (pt) Inibidores de calicreína plasmática
MX2023011875A (es) Tratamiento genico para miocardiopatía arritmogénica del ventriculo derecho.
MX2023006153A (es) Terapias genicas para enfermedad neurodegenerativa.
MX2022014888A (es) Propanodioles mononitrosilados y bisnitrosilados para su uso terapéutico.
MX2023006445A (es) Composiciones y usos de estas para el tratamiento del síndrome de angelman.
MX2025000757A (es) Casetes reguladores específicos del músculo
AR122957A1 (es) Composiciones útiles para el tratamiento de la enfermedad de charcot-marie-tooth
CL2024003524A1 (es) Composiciones y métodos para el tratamiento de la discapacidad auditiva no asociada a la edad en un sujeto humano